JP2019108366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019108366A5 JP2019108366A5 JP2019038349A JP2019038349A JP2019108366A5 JP 2019108366 A5 JP2019108366 A5 JP 2019108366A5 JP 2019038349 A JP2019038349 A JP 2019038349A JP 2019038349 A JP2019038349 A JP 2019038349A JP 2019108366 A5 JP2019108366 A5 JP 2019108366A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- compound
- formula
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 239000002270 dispersing agent Substances 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 238000007922 dissolution test Methods 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- ZFHQRKNHABBCOO-MONFIQOXSA-N (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide trihydrate Chemical compound O.O.O.C[C@@H]1[C@@H](C[C@@H](C(N1CC(F)(F)F)=O)NC(=O)C=1C=C2C(=NC1)C[C@]1(C2)C(NC2=NC=CC=C21)=O)C2=CC=CC=C2 ZFHQRKNHABBCOO-MONFIQOXSA-N 0.000 claims 1
- DDOOFTLHJSMHLN-ZQHRPCGSSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=CC=CC=C1 DDOOFTLHJSMHLN-ZQHRPCGSSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical group CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936019P | 2014-02-05 | 2014-02-05 | |
| US61/936,019 | 2014-02-05 | ||
| US201462087366P | 2014-12-04 | 2014-12-04 | |
| US62/087,366 | 2014-12-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548023A Division JP6491669B2 (ja) | 2014-02-05 | 2015-01-30 | Ｃｇｒｐ活性化合物の錠剤製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019108366A JP2019108366A (ja) | 2019-07-04 |
| JP2019108366A5 true JP2019108366A5 (https=) | 2019-11-21 |
| JP6666490B2 JP6666490B2 (ja) | 2020-03-13 |
Family
ID=53778348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548023A Active JP6491669B2 (ja) | 2014-02-05 | 2015-01-30 | Ｃｇｒｐ活性化合物の錠剤製剤 |
| JP2019038349A Active JP6666490B2 (ja) | 2014-02-05 | 2019-03-04 | Ｃｇｒｐ活性化合物の錠剤製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548023A Active JP6491669B2 (ja) | 2014-02-05 | 2015-01-30 | Ｃｇｒｐ活性化合物の錠剤製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10117836B2 (https=) |
| EP (1) | EP3102564A4 (https=) |
| JP (2) | JP6491669B2 (https=) |
| KR (3) | KR20230107902A (https=) |
| CN (2) | CN105960397B (https=) |
| AU (5) | AU2015214502B2 (https=) |
| CA (1) | CA2937315A1 (https=) |
| HK (1) | HK1232218A1 (https=) |
| IL (1) | IL246828B (https=) |
| MX (2) | MX383378B (https=) |
| RU (2) | RU2019123406A (https=) |
| SA (1) | SA516371613B1 (https=) |
| WO (1) | WO2015119848A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI501968B (zh) * | 2010-11-12 | 2015-10-01 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| RU2019123406A (ru) | 2014-02-05 | 2019-10-03 | Мерк Шарп И Доум Корп. | Технология приготовления таблеток для cgrp-активных соединений |
| CN105126111A (zh) * | 2015-09-30 | 2015-12-09 | 清华大学 | 提高索拉非尼生物利用度的制剂 |
| HRP20231748T1 (hr) * | 2017-03-30 | 2024-03-15 | Merck Patent Gmbh | Farmaceutska formulacija |
| MX2020009856A (es) * | 2018-03-25 | 2020-10-08 | Biohaven Pharm Holding Co Ltd | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| RU2755571C1 (ru) * | 2020-06-09 | 2021-09-17 | Сергей Геннадьевич Каплунов | Способ изготовления гравюры на металле |
| CN116390712A (zh) | 2020-07-29 | 2023-07-04 | 阿勒根制药国际有限公司 | 治疗偏头痛 |
| CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
| WO2022109077A1 (en) * | 2020-11-19 | 2022-05-27 | Biohaven Pharmaceutical Holding Company Ltd. | Compositions for improved delivery of cgrp inhibitors |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CA3206675A1 (en) * | 2021-02-02 | 2022-08-11 | Markus Von Raumer | A crystalline form of (4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(r)-3-(3-[1,2,3]triazol-2-yl-benzyl)-morpholin-4-yl]-methanone |
| EP4408418A1 (en) | 2021-09-27 | 2024-08-07 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| DE3612212A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
| TW486370B (en) | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
| US6103260A (en) * | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
| US20040076668A1 (en) * | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
| AU2004222378B2 (en) | 2003-03-14 | 2008-08-14 | Merck Sharp & Dohme Corp. | Carboxamide spirohydantoin CGRP receptor antagonists |
| CA2519515A1 (en) | 2003-03-14 | 2004-10-14 | Merck & Co., Inc. | Benodiazepine spirohydantoin cgrp receptor antagonists |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| CA2579847A1 (en) | 2004-09-13 | 2006-03-23 | Merck & Co., Inc. | Bicyclic anilide spirolactam cgrp receptor antagonists |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| DE102004063755A1 (de) * | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
| CA2599925A1 (en) | 2005-03-14 | 2006-09-21 | Merck & Co., Inc. | Cgrp receptor antagonists |
| WO2007092642A2 (en) | 2006-02-09 | 2007-08-16 | Merck & Co., Inc. | Polymer formulations of cetp inhibitors |
| AU2007284994B2 (en) | 2006-05-09 | 2010-04-22 | Merck Sharp & Dohme Corp. | Substituted spirocyclic CGRP receptor antagonists |
| CA2689217C (en) | 2007-06-05 | 2016-02-16 | Merck & Co., Inc. | Carboxamide heterocyclic cgrp receptor antagonists |
| KR20100091972A (ko) | 2007-10-18 | 2010-08-19 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｇｒｐ 길항제 |
| WO2009065922A2 (de) | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | Organische verbindungen |
| CA2722536A1 (en) * | 2008-02-05 | 2009-08-13 | Merck & Co., Inc. | Prodrugs of cgrp receptor antagonist |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| CN102065842A (zh) | 2008-04-15 | 2011-05-18 | 先灵公司 | 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物 |
| WO2010114801A1 (en) * | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| WO2010139717A1 (de) | 2009-06-05 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Neue verbindungen |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| TWI501968B (zh) | 2010-11-12 | 2015-10-01 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| WO2012064911A1 (en) | 2010-11-12 | 2012-05-18 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide indane cgrp receptor antagonists |
| WO2013066360A1 (en) | 2010-12-22 | 2013-05-10 | Merck Sharp & Dohme Corp. | Fused heterocyclic azaindane carboxamide cgrp receptor antagonists |
| US8895572B2 (en) | 2010-12-22 | 2014-11-25 | Merck Sharp & Dohme Corp. | Fused heterocyclic indane carboxamide CGRP receptor antagonists |
| US8591944B2 (en) * | 2011-03-08 | 2013-11-26 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| EP2685826B1 (en) | 2011-03-18 | 2016-02-03 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
| WO2013036861A1 (en) | 2011-09-08 | 2013-03-14 | Codexis, Inc | Biocatalysts and methods for the synthesis of substituted lactams |
| WO2013056108A2 (en) | 2011-10-14 | 2013-04-18 | Array Biopharma Inc. | Solid dispersion |
| KR102061180B1 (ko) | 2012-03-14 | 2019-12-31 | 머크 샤프 앤드 돔 코포레이션 | 비대칭 상 이동 촉매로서의 비스-4급 신코나 알칼로이드 염 |
| US9487523B2 (en) | 2012-03-14 | 2016-11-08 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| US9833488B2 (en) | 2012-04-25 | 2017-12-05 | Centric Research Institute | Sensitization composition and method of use |
| US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| EP2846799B1 (en) | 2012-05-09 | 2017-11-15 | Merck Sharp & Dohme Corp. | Spirolactam cgrp receptor antagonists |
| EP2846801B1 (en) | 2012-05-09 | 2017-04-05 | Merck Sharp & Dohme Corp. | Pyridine cgrp receptor antagonists |
| EP2846798B1 (en) | 2012-05-09 | 2018-04-04 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam cgrp receptor antagonists |
| SMT202400324T1 (it) | 2013-03-15 | 2024-11-15 | Tonix Pharma Ltd | Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo |
| BR112016005589B8 (pt) | 2013-09-16 | 2023-04-18 | Merck Sharp & Dohme | Composição farmacêutica líquida, e, uso da mesma |
| RU2019123406A (ru) | 2014-02-05 | 2019-10-03 | Мерк Шарп И Доум Корп. | Технология приготовления таблеток для cgrp-активных соединений |
| WO2015120014A1 (en) | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| JP2017512757A (ja) | 2014-02-24 | 2017-05-25 | ウリゲン ファーマシューティカルズ、インコーポレイテッド | 経口投与するためのペントサンポリ硫酸塩の組成物および使用の方法 |
| AU2015305696B2 (en) | 2014-08-22 | 2019-08-29 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
| JP6673924B2 (ja) | 2015-01-23 | 2020-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
| MX2018003713A (es) | 2015-09-24 | 2018-08-15 | Teva Pharmaceuticals Int Gmbh | Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente). |
| US20180092899A1 (en) | 2016-09-30 | 2018-04-05 | Merck Sharp & Dohme Corp. | Method of treating acute migraine with cgrp-active compound |
| RU2770066C2 (ru) | 2017-03-02 | 2022-04-14 | Бет Изрейэл Диконисс Медикал Сентер, Инк. | Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида |
| TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
| US20190135927A1 (en) | 2017-09-29 | 2019-05-09 | Bhl Patent Holdings, Llc | Migraine, headache, chronic pain treatment, and prophylaxis options |
| US20190374520A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US20190374518A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| TWI826514B (zh) | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| AU2020259461A1 (en) | 2019-04-18 | 2021-11-11 | Allergan Sales, Llc | CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
| WO2021062282A1 (en) | 2019-09-25 | 2021-04-01 | Allergan Pharmaceuticals International Limited | Combination therapy with cgrp antagonists |
| CN116390712A (zh) | 2020-07-29 | 2023-07-04 | 阿勒根制药国际有限公司 | 治疗偏头痛 |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| EP4408418A1 (en) | 2021-09-27 | 2024-08-07 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
-
2015
- 2015-01-30 RU RU2019123406A patent/RU2019123406A/ru unknown
- 2015-01-30 KR KR1020237022803A patent/KR20230107902A/ko not_active Ceased
- 2015-01-30 WO PCT/US2015/013672 patent/WO2015119848A1/en not_active Ceased
- 2015-01-30 CA CA2937315A patent/CA2937315A1/en active Pending
- 2015-01-30 CN CN201580006288.6A patent/CN105960397B/zh active Active
- 2015-01-30 JP JP2016548023A patent/JP6491669B2/ja active Active
- 2015-01-30 MX MX2016010169A patent/MX383378B/es unknown
- 2015-01-30 AU AU2015214502A patent/AU2015214502B2/en active Active
- 2015-01-30 CN CN202010812438.5A patent/CN112022818A/zh active Pending
- 2015-01-30 HK HK17105813.5A patent/HK1232218A1/zh unknown
- 2015-01-30 US US15/115,026 patent/US10117836B2/en active Active
- 2015-01-30 KR KR1020227032939A patent/KR20220136460A/ko not_active Ceased
- 2015-01-30 RU RU2016135536A patent/RU2696578C1/ru active
- 2015-01-30 KR KR1020167024025A patent/KR102448369B1/ko active Active
- 2015-01-30 EP EP15746768.9A patent/EP3102564A4/en active Pending
-
2016
- 2016-07-18 IL IL246828A patent/IL246828B/en active IP Right Grant
- 2016-08-04 SA SA516371613A patent/SA516371613B1/ar unknown
- 2016-08-04 MX MX2021006790A patent/MX2021006790A/es unknown
-
2018
- 2018-11-02 US US16/178,641 patent/US20190209478A1/en not_active Abandoned
-
2019
- 2019-03-04 JP JP2019038349A patent/JP6666490B2/ja active Active
- 2019-09-06 AU AU2019226239A patent/AU2019226239B2/en active Active
-
2020
- 2020-12-03 US US17/110,398 patent/US11925709B2/en active Active
-
2021
- 2021-10-08 AU AU2021245229A patent/AU2021245229A1/en not_active Abandoned
-
2023
- 2023-04-21 US US18/137,925 patent/US20230248655A1/en not_active Abandoned
- 2023-10-30 AU AU2023258317A patent/AU2023258317A1/en not_active Abandoned
-
2025
- 2025-08-22 AU AU2025220825A patent/AU2025220825A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019108366A5 (https=) | ||
| CN1163223C (zh) | 肠内目标部位释放型制剂 | |
| CN113274355B (zh) | 利福昔明固体分散体 | |
| ES2337935T3 (es) | Comprimidos de accion retardada con hidromorfona. | |
| JPH09143073A (ja) | 持続性ニフエジピン製剤 | |
| TW200301139A (en) | Zero-order sustained release dosage forms and method of making same | |
| JP5948648B2 (ja) | 安定化されたエペリゾンを含有する徐放性製剤 | |
| EP2405900A2 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| WO2006082523A2 (en) | Pharmaceutical sustained release composition of metformin | |
| CN107205950B (zh) | 金刚烷胺组合物的施用方法 | |
| TW201113050A (en) | 3-cyanoquinoline tablet formulations and uses thereof | |
| CN101854929A (zh) | 新型制剂 | |
| WO2018108157A1 (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
| JP2017518985A (ja) | アリサルタン・イソプロキシル固体分散体及び医薬組成物 | |
| CN106511312A (zh) | 一种复方西地那非达泊西汀缓释胶囊及其制备方法 | |
| Aslam et al. | Techniques and polymers used to design Gastroretentive drug delivery systems–a review | |
| CN101011393B (zh) | 厄贝沙坦胃内滞留型缓释药物组合物 | |
| ES2899885T3 (es) | Nueva composición farmacéutica de liberación diferencial que contiene tres principios activos | |
| JP2025078766A (ja) | ピリミジニルアミノピラゾール化合物の調節放出製剤および処置方法 | |
| CN116059175B (zh) | 一种普瑞巴林胃漂浮缓释片及其制备方法 | |
| JPS61286330A (ja) | 経口徐放性製剤 | |
| JP5919173B2 (ja) | 徐放性塩酸アンブロキソール口腔内崩壊錠 | |
| JP3007387B2 (ja) | 徐放性製剤用基剤粉末 | |
| CN107249569A (zh) | 一种包含含有盐酸坦索罗辛的缓释颗粒的口服药物制剂 | |
| WO2009076754A1 (en) | Single layered controlled release therapeutic system |